Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Neurobiol Dis. 2019 Jun 15;130:104508. doi: 10.1016/j.nbd.2019.104508

Figure 5: Gli1 and Smo expression are not affected by miR-324-5p inhibition in epileptic mice.

Figure 5:

(A,B) In contrast to Kv4.2 mRNA, association of Gli1 (A) and Smo (B) mRNA with Ago2 is not significantly changed in epileptic mice after miR-324-5p inhibition (SCR: n=8, a-324-5p: n=7, unpaired one-tailed t-test, A: t(13)=1.087, p=0.148; B: t(13)=0.836, p=0.209). (C-E) Likewise, neither Gli1 protein (C) nor Gli1 (D) or Smo (E) mRNA are affected by the in vivo antagomir treatment (C: n=9, unpaired one-tailed t-test, t(16)=0.450, p=0.330; D: SCR: n=9, a-324-5p: n=7, unpaired one-tailed t-test, t(14)=0.039, p=0.485; E: SCR: n=9, a-324-5p: n=7, one-tailed Mann-Whitney test, p=0.105). Example western blot of two mice per condition (#1-4, loaded in duplicates) for C shown at top. Ago-IPs were normalized to input. Error bars represent SEM.

HHS Vulnerability Disclosure